Home » Novo Says Momentum Is Still There After U.S. Insulin Setback
Novo Says Momentum Is Still There After U.S. Insulin Setback
Novo Nordisk’s chief scientist says that even though the FDA rejected the drugmaker’s Tresiba insulin product earlier this year, the company is moving forward on several more products this year.
Bloomberg
Bloomberg
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May